BioSpace News Archive

He succeeds James Abell who is retiring after 21 years with the firm.

FETROJA demonstrated higher response rates versus imipenem/cilastatin in a cUTI study

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the pricing of its public offering of 4,077,192 shares of its common stock at a public offering price of $36.75 per share

Panasonic Corporation took part in the 2nd China International Import Expo (CIIE) 2019, which was held in Shanghai from November 5 to 10.

Today’s approval provides an additional treatment option for patients with cUTIs who have limited or no alternative treatment options

All financial results are prepared in accordance with International Financial Reporting Standards (“IFRS”) and are reported in U.S. dollars, unless otherwise stated.

Quarterly and YTD Reduction in Net Loss Compared to Prior Year

This new patent issuance increases B&D’s total patent portfolio to 12 issued patents, 8 of which are specifically related to dental zirconia and coloring.

Shockwave Medical, Inc. announced the pricing of its public offering of 2,481,781 shares of its common stock at a price to the public of $36.25 per share. All of the shares are being offered by Shockwave.

Trial meets its Primary Endpoint with 39% ORR (95%CI 22%-58%) in patients with advanced PEComa – a rare sarcoma with no currently approved therapy